Market Overview

Phillips-Medisize Enhances Integrated Connected Health Platform

Share:

Building on a scalable technology that benefits pharma clients and
their providers and patients

Phillips-Medisize,
a Molex company
, announced the release of its third generation
connected health platform, a service offering for its pharma and drug
delivery device clients. The platform builds on the success of the
company's first connected health solutions, including the first
FDA-approved combination product for medication adherence, and
incorporates more than a decade of experience in developing connected
health solutions.

Utilizing connectivity in drug delivery devices such as injectors and
inhalers, connected health solutions help pharmaceutical companies,
healthcare professionals and patients, improve how people take their
medication. In addition to medication tracking, these systems support
patients through reminders, incentives and peer communities to improve
disease management, medication adherence and, ideally, outcomes.

Phillips-Medisize teamed with industry-leading healthcare IT providers
to develop a platform that addresses the key challenges faced by the
industry. The cloud-based third generation connected health platform is
a secure, reliable and scalable medical device data system (MDDS). Using
an industry-leading health integration engine combined with a rich
analytics tool, it can integrate patient data with electronical medical
records and other data from pharmacy and IoT devices, allowing customers
to conduct insightful analysis focused on improving medication adherence.

"Phillips-Medisize is a leader in connected health systems for medicine
currently on the market, supporting patients daily across the globe.
This new, advanced connected health platform builds on our deep
knowledge and experience," said Bill Welch, Chief Technology Officer,
Phillips-Medisize. "For us, connected health is a strategy for better
serving our customers and their patients, not a buzz word. We are
unmatched in the industry with our global innovation, development and
manufacturing capabilities to create end-to-end systems."

As connected health systems begin to demonstrate incremental
improvements in adherence and patient outcomes, Phillips-Medisize
expects the market to grow. The third generation platform further
demonstrates the company's commitment to meeting industry, provider and
patient needs by building technology that is sensible, scalable and
cost-effective.

For more information about Phillips-Medisize Connected Health
capabilities, please visit www.phillipsmedisize.com
or www.molex.com.

About Phillips-Medisize:

Phillips-Medisize, LLC, a Molex company, is a leading global outsource
provider of design and manufacturing services to the drug delivery,
consumable diagnostics, medical device and specialty commercial markets.
Backed by the combined global resources of Molex and its parent company
Koch Industries, Phillips-Medisize's core advantage is the knowledge of
its people to integrate design, molding and automation, providing
innovative, high-quality manufacturing solutions. For more information,
please visit www.phillipsmedisize.com
or www.molex.com.

View Comments and Join the Discussion!